JPMorgan Chase & Co. Acquires 395,739 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

JPMorgan Chase & Co. increased its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 133.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 693,106 shares of the company’s stock after acquiring an additional 395,739 shares during the quarter. JPMorgan Chase & Co. owned about 0.47% of MiMedx Group worth $6,668,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Jane Street Group LLC increased its holdings in shares of MiMedx Group by 133.6% during the third quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock worth $1,806,000 after purchasing an additional 174,797 shares during the period. Barclays PLC grew its position in MiMedx Group by 163.9% during the third quarter. Barclays PLC now owns 262,449 shares of the company’s stock worth $1,550,000 after buying an additional 163,005 shares in the last quarter. SG Americas Securities LLC grew its position in MiMedx Group by 79.9% during the fourth quarter. SG Americas Securities LLC now owns 83,385 shares of the company’s stock worth $802,000 after buying an additional 37,031 shares in the last quarter. Principal Financial Group Inc. increased its stake in MiMedx Group by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock worth $328,000 after acquiring an additional 3,292 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in MiMedx Group by 0.7% in the 4th quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company’s stock valued at $4,849,000 after acquiring an additional 3,300 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MDXG. StockNews.com cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th.

Insider Activity at MiMedx Group

In related news, insider Kimberly Maersk-Moller sold 4,106 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the sale, the insider now owns 310,836 shares of the company’s stock, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO William Frank Iv Hulse sold 54,596 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $430,762.44. Following the sale, the chief accounting officer now owns 440,178 shares in the company, valued at $3,473,004.42. This represents a 11.03 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 144,018 shares of company stock valued at $1,130,312. 1.30% of the stock is owned by insiders.

MiMedx Group Trading Up 0.7 %

Shares of MDXG stock opened at $6.68 on Friday. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The stock’s fifty day moving average price is $7.72 and its two-hundred day moving average price is $8.00. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The company has a market cap of $983.67 million, a PE ratio of 12.14 and a beta of 1.74.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. The business had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Equities analysts predict that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.